Emerald Health Therapeutics Inc EMHTF

Emerald Health Therapeutics Announces At-the-Market Equity

[tradecat]

Emerald Health Therapeutics Announces At-the-Market Equity Program NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES Emerald Health Therapeutics, Inc. ("Emerald" or the "Company") (TSXV:EMH; OTCQX:EMHTF) today announced that it has established an at-the-market equity program ("ATM Program") that allows the Company to issue common shares from treasury ("Common Shares") having an aggregate gross sales price of up to $39 million to the public from time to time, at the Company's discretion, at the prevailing market price when issued on the TSX Venture Exchange ("TSXV") or on any other marketplace for the Common Shares in Canada. The ATM Program is effective until the earlier of April 13, 2021 or completion of the sale of the maximum amount of shares thereunder and will be activated from time to time at the Company's discretion if and when required based on the Company's working capital requirements and capital expenditures and relative cost of other funding options. Sales of the Common Shares through the ATM Program will be made pursuant to the terms of an equity distribution agreement dated as of the date hereof ("Equity Distribution Agreement") with GMP Securities L.P. (the "Agent"). Sales of Common Shares will be made through "at-the-market distributions" as defined in National Instrument 44-102 - Shelf Distributions on the TSXV or on any other existing marketplace for the Common Shares in Canada. The Common Shares will be distributed at the prevailing market prices at the time of the sale and, as a result, prices may vary among purchasers and during the period of distribution. The ATM Offering is being made pursuant to a prospectus supplement dated March 27, 2019 (the "Prospectus Supplement") to the Company's short form base shelf prospectus dated March 13, 2019 (the "Base Shelf Prospectus"). The Company expects to use the net proceeds of the ATM Program, if any, to fund a portion of the costs for the completion of its capital projects, for research and development, working capital and general corporate purposes. The Prospectus Supplement (together with the related Base Shelf Prospectus) is available under the Company's profile on the SEDAR website maintained by the Canadian Securities Administrators at www.sedar.com. The Company has applied for conditional approval from the TSXV for the listing of the Common Shares to be offered under the ATM Program. This news release will not constitute an offer to sell or the solicitation of an offer to buy nor will there be any sale of the securities in any jurisdiction in which such offer, solicitation, or sale would be unlawful.

[goal111]

there we go, be prepared for Delta phase 2 expansion news. Soon to be announced!

[cannhealth]

I'll be watching with extreme interest to see why, when and how much of the 150MM base shelf prospectus (up to $39MM per offering) the company will be utilizing over the next two years. Goal.. I doubt you'll see D2 expansion in the immediate future as EMH is charting it's own path with more immediate, revenue generating projects. The ATM cap per offering of $39MM is measured, somewhat

[billy4325]

Not expanding D2 would be extremely stupid but you're right that management may do something else, like grossly overpaying on useless related companies.

[futureboss]

Best option is to build out Delta along with a state of the art extraction facility..seems to be a no brainer. 

[MarketFix]

Yes that’s it, no brain

[VENMan]

The offering is capped at $39M and from what i read in the news release there was no mention of any  Units with warrants attached so as i understand it they will issue common stock as money is needed up to  $39M during a 2 year period. The whole $39M at $4 right now would add 9.7M common stock to the current float of 142M common stock. So worse cause 152M common stock (not fully diluted)